Citius Oncology, Inc. Earnings Per Share (Basic)
Citius Oncology, Inc. (CTOR) reported Earnings Per Share (Basic) of -$0.08 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-14
- Citius Oncology, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$0.08.
- Citius Oncology, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$0.27.
- Citius Oncology, Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$0.06.
- Citius Oncology, Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$0.06.
- Citius Oncology, Inc. earnings per share, basic for fiscal 2025 was -$0.34.
- Citius Oncology, Inc. earnings per share, basic for fiscal 2024 was -$0.31.
- Citius Oncology, Inc. earnings per share, basic for fiscal 2023 was $0.27.
- Citius Oncology, Inc. earnings per share, basic for fiscal 2023 was -$0.19.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 7 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 10 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$0.08 10-Q · filed 2026-08-14 | -$0.34 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$0.42 10-Q · filed 2026-08-14 | -$0.49 derived: net income ÷ weighted average shares · filed 2026-08-14 | |||
| 2026-03-31 | -$0.27 10-Q · filed 2026-05-15 | -$0.34 10-Q · filed 2026-05-15 | -$0.42 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$0.50 derived: net income ÷ weighted average shares · filed 2026-08-14 | |||
| 2025-12-31 | -$0.06 10-Q · filed 2026-02-13 | -$0.13 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$0.20 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$0.31 derived: net income ÷ weighted average shares · filed 2026-08-14 | |||
| 2025-09-30 | -$0.06 derived: net income ÷ weighted average shares · filed 2025-12-23 | -$0.14 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$0.25 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$0.34 10-K · filed 2025-12-23 | |||
| 2025-06-30 | -$0.08 10-Q · filed 2026-08-14 | -$0.18 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$0.28 10-Q · filed 2026-08-14 | -$0.37 derived: net income ÷ weighted average shares · filed 2026-08-14 | |||
| 2025-03-31 | -$0.11 10-Q · filed 2026-05-15 | -$0.20 10-Q · filed 2026-05-15 | -$0.30 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$0.37 derived: net income ÷ weighted average shares · filed 2026-08-14 | |||
| 2024-12-31 | -$0.09 10-Q · filed 2026-02-13 | -$0.19 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$0.26 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$0.33 derived: net income ÷ weighted average shares · filed 2026-08-14 | |||
| 2024-09-30 | -$0.10 derived: net income ÷ weighted average shares · filed 2025-12-23 | -$0.17 derived: net income ÷ weighted average shares · filed 2025-12-23 | -$0.24 derived: net income ÷ weighted average shares · filed 2025-12-23 | -$0.31 10-K · filed 2025-12-23 | |||
| 2024-06-30 | -$0.07 10-Q · filed 2025-08-12 | $0.04 10-Q · filed 2024-08-09 | $0.11 10-Q · filed 2024-08-09 | -$0.21 10-Q · filed 2025-08-12 | -$0.27 derived: net income ÷ weighted average shares · filed 2025-08-12 | ||
| 2024-03-31 | -$0.07 10-Q · filed 2025-05-14 | $0.07 10-Q · filed 2024-05-20 | -$0.14 10-Q · filed 2025-05-14 | -$0.20 derived: net income ÷ weighted average shares · filed 2025-08-12 | -$0.24 derived: net income ÷ weighted average shares · filed 2025-08-12 | ||
| 2023-12-31 | -$0.07 10-Q · filed 2025-02-14 | -$0.12 derived: net income ÷ weighted average shares · filed 2025-08-12 | -$0.15 derived: net income ÷ weighted average shares · filed 2025-08-12 | $0.27 10-K · filed 2024-04-16 | |||
| 2023-09-30 | $0.02 10-Q · filed 2023-11-20 | $0.12 derived: net income ÷ weighted average shares · filed 2024-08-09 | $0.15 10-Q · filed 2023-11-20 | -$0.19 10-K · filed 2024-12-27 | |||
| 2023-06-30 | $0.07 10-Q · filed 2024-08-09 | $0.14 10-Q · filed 2024-08-09 | |||||
| 2023-03-31 | $0.07 10-Q · filed 2024-05-20 | ||||||
| 2022-12-31 | $0.12 10-K · filed 2024-04-16 | ||||||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-20 | $0.00 10-Q · filed 2023-11-20 | |||||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-16 | $0.00 10-Q · filed 2023-08-16 | |||||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-15 | ||||||
| 2021-12-31 | -$0.01 10-K · filed 2023-04-17 | ||||||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-28 | -$0.01 10-Q · filed 2022-11-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |